Delegation to BIO stamps Australia as a world leader in biotech
23 September, 2014This year, Australia stamped its presence on the 2014 BIO International Convention with more than 250 delegates from Australia attending BIO 2014, making Australia the eighth-largest international delegation. Australia's continuing presence at BIO coincides with Australia's growing reputation as one of the world leaders in biotechnology.
Clinuvel enters dermatology drug JV
23 September, 2014 by Dylan Bushell-EmblingClinuvel (ASX:CUV) will form a joint venture with Biotech Lab Singapore to develop paediatric versions of Scenesse and a new dermatology drug candidate.
Minomic launches US pilot trial for MiSat
22 September, 2014 by Dylan Bushell-EmblingMinomic International has commenced a US pilot trial of prostate cancer screening test MiSat and plans to use the results to inform a larger trial and an FDA submission.
EndoBarrier reduces heart risk during studies
19 September, 2014 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) has announced data showing that obese patients treated with its EndoBarrier device showed reduced 10-year cardiovascular risk.
Survey to support manufacturing exporters to compete internationally
18 September, 2014The Export Council of Australia (ECA) and the Manufacturing Excellence Taskforce Australia (META) have established a Deregulation Hub, with the purpose of producing an Agenda for Action to inform government on the streamlining of regulation that inhibits the ability of Australian manufacturers to compete internationally.
R&D Tax Incentive - overseas R&D activities update
18 September, 2014An update for companies on what "not available in Australia" means for meeting the requirements to make a claim for R&D activities conducted outside of Australia.
Orthocell, Antisense bolster IP portfolios
17 September, 2014 by Dylan Bushell-EmblingOrthocell (ASX:OTI) has been granted an Australian patent for its regenerative product Ortho-ATI, while Antisense Therapeutics (ASX:ANP) will soon obtain a European patent for ATL1102.
Vaxxas, WHO explore Nanopatch polio vaccines
17 September, 2014 by Dylan Bushell-EmblingThe WHO will fund research into using Vaxxas's Nanopatch vaccine delivery technology to help finally eradicate polio worldwide.
Simavita's US partner wins first big contract
17 September, 2014 by Dylan Bushell-EmblingSimavita's (ASX:SVA) exclusive US distribution partner Medline has picked up its first major supply contract for the Smart Incontinence Management (SIM) medical device.
Prestigious International Biotechnology Symposium coming down under
16 September, 2014In a major coup for the biotechnology industry in Australia, the prestigious International Biotechnology Symposium (IBS) will be held in Melbourne in 2016 in conjunction with the AusBiotech 2016 national conference and Australia Biotech Invest 2016 - making it the largest biotech industry event in Australia's history.
Nexvet expands veterinary biologics research team
15 September, 2014 by Dylan Bushell-EmblingTwo former CSL (ASX:CSL) scientists have joined Nexvet's veterinary biologics research centre in Melbourne.
Calzada, pSivida, GI Dynamics announce board moves
12 September, 2014 by Dylan Bushell-EmblingCalzada (ASX:CZD) has announced the resignation of an independent director, while GI Dynamics (ASX:GID) and pSivida (ASX:PVA) have selected new members for their own boards.
Global Kinetics gets FDA clearance for PKG
11 September, 2014 by Dylan Bushell-EmblingGlobal Kinetics has been cleared to sell the Australian-made Parkinson's KinetiGraph wearable symptom monitoring device in the US.
AusBiotech calls for nominations to the board of directors
11 September, 2014Further to the notice of the forthcoming election for AusBiotech's board of directors, nominations are now open for eligible AusBiotech members.
Iluvien approved in 10th EU market: pSivida
11 September, 2014 by Dylan Bushell-EmblingpSivida (ASX:PVA) licensee Alimera Sciences has got the marketing nod in Sweden for DMO treatment Iluvien, marking its 10th EU approval.
